BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Vitae Scores 'BACE' Hit, Signs $242M Alzheimer's Deal with BI
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Vitae Scores 'BACE' Hit, Signs $242M Alzheimer's Deal with BI
June 16, 2009
By
Jennifer Boggs
No Comments
Vitae Pharmaceuticals Inc. is getting $42 million up front in an early stage deal with Boehringer Ingelheim GmbH aimed at the much-sought-after - though difficult - space of disease-modifying drugs against Alzheimer's disease. (BioWorld Today)
BioWorld